Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Greenwich LifeSciences, Inc. Frequently Asked Questions
What is the ticker symbol for Greenwich LifeSciences, Inc.? What does GLSI stand for in stocks?
GLSI is the stock ticker symbol of Greenwich LifeSciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Greenwich LifeSciences, Inc. (GLSI)?
As of Fri Nov 22 2024, market cap of Greenwich LifeSciences, Inc. is 176.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of GLSI stock?
You can check GLSI's fair value in chart for subscribers.
Is Greenwich LifeSciences, Inc. a good stock to buy?
The fair value guage provides a quick view whether GLSI is over valued or under valued. Whether Greenwich LifeSciences, Inc. is cheap or expensive depends on the assumptions which impact Greenwich LifeSciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GLSI.